Podcast Atlas
Source note Episode guide Original audio Tags: Podcast, All-In, Psychedelics, Longevity, Neuroscience

Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World… Here’s What It Was Like

Summary

This All-In episode has Bryan Johnson describing a recent 5-MeO-DMT self-experiment as part of his broader longevity program. He frames psychedelics not only as ritual, recreation, or psychiatric therapy, but as possible interventions for default-mode-network reset, neuroplasticity, inflammation, metabolism, and subjective psychological rejuvenation.

The hosts press the risk side: psychosis, bad trips, founder life disruption, changed values, family responsibility, and whether radical self-modification preserves personal continuity. The episode then broadens from psychedelics into mitochondrial therapy, gene and cell therapies, patient-derived organoids, cellular reprogramming control risk, NewLimit, and GLP-1 agonists as signals of a wider biological-intervention era.

Key Claims

  • Johnson says he took 5-MeO-DMT shortly before recording, using a 9 mg intramuscular dose followed by vaporized dosing, and describes the effect as faster and more overwhelming than prior psychedelic experiences.
  • He presents the experiment as part of a ranked longevity-intervention project that had already emphasized exercise, nutrition, sleep, sauna, hyperbaric oxygen, rapamycin, and metformin before psychedelics entered the frame.
  • The source treats Johnson’s psilocybin work as the bridge case: he says three 25 mg doses were measured through Kernel, MRI, and other tools and appeared to change brain connectivity, glucose percentile, inflammation, and microbiome markers.
  • Johnson argues that psychedelic value may come partly through disrupting or relaxing the default mode network, which he associates with ego, rumination, defensive thought loops, and adult psychological rigidity.
  • The source keeps the 5-MeO evidence boundary clear: Johnson says objective 5-MeO results were not available yet, so the episode’s strongest claims are immediate subjective reports rather than completed biological data.
  • Johnson describes aftereffects as childlike playfulness, faster conversational access, reduced defensiveness in conflict, and a sense of psychological renewal.
  • The hosts and Johnson repeatedly stress medical risk management: unknown doses, poor set and setting, predisposition to psychosis, and lack of supervision can make psychedelic use dangerous.
  • The episode creates a psychedelic identity disruption branch by asking whether intense experiences can make founders leave companies, people leave families or religions, or values change enough to alter obligations.
  • Johnson says the experience made him more motivated to continue his work, not less, but also says he has no fixed personal limit on future self-modification through neural devices, transgenic systems, plasmids, or gene-expression changes.
  • The longevity section links mitochondrial augmentation, cell therapy, gene therapy, organoid pretesting, and Yamanaka-factor reprogramming to the same frontier-health mindset.
  • The source frames GLP-1 drugs as a possible public normalization step for injectable biological interventions, while treating deeper rejuvenation therapies as still emerging and safety-constrained.

Key Quotes

“raw consciousness” - Johnson’s phrase for the 5-MeO-DMT experience.

“panic and surrender” - the central choice Johnson says the experience presents.

“30 or 40 years of psychological rejuvenation” - Johnson’s subjective description of the aftereffect.

Connections

Contradictions

  • No direct contradiction found with existing wiki content.
  • The source extends DMT without replacing the existing psychedelic-church/legal frame: it distinguishes 5-MeO-DMT as Johnson’s biomedical self-experiment rather than treating it as the same sacramental access case.
  • The source qualifies Self-Experimentation and Tech-Culture Biohacking by showing a more measured and supervised version of elite biohacking, while still leaving single-subject evidence and serious medical risk unresolved.